Psilocybin, a psychedelic compound in certain mushrooms, has been used for centuries in spiritual ceremonies and neuropsychiatric therapy. Despite its stigmatization as a Schedule I substance in 1970, research into psilocybin has resurged since the early 2000s, particularly in psychiatry and palliative care. This review examines psilocybin's potential to improve the quality of life in palliative care by reducing psychological distress and enhancing emotional well-being. The discussion includes its historical context, pharmacokinetics, pharmacodynamics, legal status, and future perspectives in palliative care.